Merck’s Two-Drug HIV Therapy Shows Strong Phase 3 Efficacy
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
Clinical Development
Advertisement
TransCode Reports Positive Phase 1a Results for TTX-MC138 in Metastatic Cancer
BOSTON, Massachusetts, October 14, 2025 — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced encouraging preliminary data from its completed...
FDA Fast-Tracks Blacksmith’s FG-2101, a Novel Antibiotic Targeting LpxC
SAN DIEGO, California, October 13, 2025 – In a major advancement for antimicrobial innovation, Blacksmith Medicines, Inc. announced that...
Sagimet Begins Phase 1 Trial of Denifanstat-Resmetirom Combo in MASH
SAN MATEO, Calif., Oct. 1, 2025 — Sagimet Biosciences announced that it has dosed the first participants in a...
Kedrion Biopharma Secures FDA Nod for QIVIGY® and Expands U.S. Growth Plan
September 29, 2025 – Kedrion Biopharma announced a major regulatory and strategic milestone with the U.S. Food and Drug...
Advertisements
European Commission Approves Henlius and Organon’s Biosimilars for Bone Disorders
SHANGHAI, China & JERSEY CITY, NJ – September 19, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN)...
Coya’s COYA 303 Shows Promise in Neuroinflammation and Treg Boost
HOUSTON, Sept. 16, 2025 – Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company specializing in regulatory T cell...
Advertisement
